Where to buy nicotine toothpicks5/29/2023 So what was it about tobacco that ravaged the heart, lungs, teeth and skin but somehow guarded against a disease of the brain? In 1979, UCLA neurobiologist Marie-Françoise Chesselet showed that nicotine increases levels of dopamine, a neurotransmitter essential for boosting attention, reward-seeking behaviors and risk of addictions, from gambling to drugs.ĭopamine also helps control movement. Sure enough, they found that the Parkinson’s patients were much less likely than other residents to have ever smoked. (The neurodegenerative disorder affects about 1 percent of people by age 60, rising to about 4 percent by age 80.)īut in 1971, epidemiologists Irving Kessler and Earl Diamond of Johns Hopkins University published a study comparing the smoking history of living Baltimore residents recently diagnosed with Parkinson’s with age-matched controls. Grasping at a final possible alternative to the inconvenient notion that smoking could have a healthful benefit, experts theorized that the association was due only to smokers dying young of cancer, heart disease and lung disease before the age when they might otherwise have developed Parkinson’s. Cohn)įollowing up, researchers expected the finding to be just a statistical aberration in Kahn’s data, but instead quickly confirmed it. A lack of dopamine has been linked to movement disorders such as Parkinson's disease. The neurotransmitter dopamine sends signals related to pleasure, reward and motor function across neurons in the brain. But amid the lineup of usual suspects, one oddball jumped out: Death due to Parkinson’s disease occurred at least three times as often in nonsmokers as in smokers. Cancers of the mouth, pharynx, esophagus, larynx - on and on. At any given age, cigarette smokers were 11 times as likely to have died of lung cancer as nonsmokers, and 12 times as likely to have died of emphysema. military between 19, Kahn found the kinds of associations between smoking and mortality that had already become well known. Using health insurance data on 293,658 veterans who had served in the U.S. The first hint of nicotine’s curious benefits came from a study published in 1966 by Harold Kahn, an epidemiologist at the National Institutes of Health. “People can’t disassociate the two in their minds.” Tweaking the Brain “The whole problem with nicotine is that it happens to be found in cigarettes,” she says. Yet over the years, she has published dozens of studies revealing the beneficial actions of nicotine within the mammalian brain. “I understand that smoking is bad,” says neuroscientist Maryka Quik, program director of the Neurodegenerative Diseases Program at SRI International, a nonprofit research institute based in California’s Silicon Valley. Heavy smokers who tried to quit without the benefit of counseling were actually twice as likely to relapse if they used a nicotine replacement product.Īnd therein lies the conundrum that physicians and regulators will have to wrestle with if the promising studies about nicotine’s benefits hold up: how to endorse a drug linked to one of the greatest public health scourges the world has ever known. In January 2012, a six-year follow-up study of 787 adults who had recently quit smoking found that those who used nicotine replacement therapy in the form of a patch, gum, inhaler or nasal spray had the same long-term relapse rate as those who did not use the products. In fact, the one purpose for which nicotine has proven futile is the very same one for which it’s approved by the Food and Drug Administration, sold by pharmacies over the counter, bought by consumers and covered by many state Medicaid programs: quitting smoking. (Although, in truth, few safety studies of the increasingly popular e-cigarettes have yet been published.) And, oh yeah, it’s long been associated with weight loss, with few known safety risks. It might even improve attention and focus enough to qualify as a cognitive enhancer. If dozens of human and animal studies published over the past six years are borne out by large clinical trials, nicotine - freed at last of its noxious host, tobacco, and delivered instead by chewing gum or transdermal patch - may prove to be a weirdly, improbably effective drug for relieving or preventing a variety of neurological disorders, including Parkinson’s disease, mild cognitive impairment (MCI), Tourette’s and schizophrenia. Now comes nicotine, perhaps the most unlikely wonder drug ever to be reviled. Even demon alcohol, when taken in moderation, cuts the risk of heart attacks, osteoporosis, rheumatoid arthritis and a hodgepodge of other ailments. Cocaine’s chemical cousin lidocaine is still used by physicians and dentists as an effective local anesthetic. Morphine remains one of the most potent painkillers ever discovered. Every drug of addiction must have its day.
0 Comments
Leave a Reply. |